Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Theravance Biopharma, Inc. (NASDAQ: TBPH).

Full DD Report for TBPH

You must become a subscriber to view this report.


Recent News from (NASDAQ: TBPH)

Theravance Biopharma Announces Closing of Private Placement of $250 Million of 9% Non-Recourse Notes
DUBLIN , Dec. 3, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" and together with its subsidiaries, the "Company") today announced the closing of a private placement of $250 million of non-recourse PhaRMA SM   9% fixed rate term notes. T...
Source: PR Newswire
Date: December, 03 2018 08:30
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease
DUBLIN , Nov. 20, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease. TD-1473 is a novel, potent, orally administe...
Source: PR Newswire
Date: November, 20 2018 08:30
Theravance Biopharma to Present at the Credit Suisse 27th Annual Healthcare Conference
DUBLIN , Nov. 7, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will present a corporate overview at the Credit Suisse 27 th Annual Healthcare Conference on Wednesday, November 14, 2018 , at 8:35 a.m. MST .  The conference will be he...
Source: PR Newswire
Date: November, 07 2018 08:30
Theravance Biopharma, Inc. (TBPH) CEO Rick Winningham on Q3 2018 Results - Earnings Call Transcript
Theravance Biopharma, Inc. (TBPH) Q3 2018 Results Earnings Conference Call November 6, 2018, 05:00 PM ET Executives Alex Dobbin - Head of IR Rick Winningham - CEO Renee Gala - CFO Brett Haumann - Chief Medical Officer Analysts Jeffrey Borges - Leerink Tyler Van Buren -...
Source: SeekingAlpha
Date: November, 06 2018 21:19
Theravance Biopharma beats by $0.06, misses on revenue
Theravance Biopharma (NASDAQ: TBPH ): Q3 GAAP EPS of -$1.10 beats by $0.06 . Revenue of $12.84M (+200.0% Y/Y) misses by $1.22M . Press Release More news on: Theravance Biopharma, Inc., Earnings news and commentary, Healthcare stocks news,
Source: SeekingAlpha
Date: November, 06 2018 16:06
Theravance Biopharma, Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the third quarter ended September 30, 2018 . Revenue for the third quarter of 2018 was $12.8 million . The Company's third quart...
Source: PR Newswire
Date: November, 06 2018 16:05
Theravance Biopharma Announces Sale of VIBATIV® (telavancin) to Cumberland Pharmaceuticals
DUBLIN , Nov. 6, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the sale of its proprietary antibiotic, VIBATIV ® (telavancin), to Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX), a specialty pharmaceutical co...
Source: PR Newswire
Date: November, 06 2018 08:30
Theravance Biopharma Is A Promising Buy Opportunity In 2018
Headquartered in the Cayman Islands, Theravance Biopharma ( TBPH ) is a biopharmaceutical company focused on therapeutic areas such as infectious, respiratory, gastrointestinal, cardiovascular, renal, inflammation and immunology diseases. The company attributes its current revenues to the ...
Source: SeekingAlpha
Date: November, 06 2018 07:10
Theravance Biopharma to Report Third Quarter 2018 Financial Results on November 6
DUBLIN , Oct. 30, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced that it will release financial results for the period ended September 30, 2018 and provide a business update after market close on Tuesday, No...
Source: PR Newswire
Date: October, 30 2018 08:30
Theravance Biopharma Reports Data from TD-1473 Phase 1b Four-Week Study in Oral Late-Breaker Presentation at UEG Week 2018
DUBLIN , Oct. 22, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today reported the results from the exploratory Phase 1b study of the gut-selective pan-Janus kinase (JAK) inhibitor TD-1473 in an oral presentation as part of...
Source: PR Newswire
Date: October, 22 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0828.6528.8629.5028.31120,871
2018-05-1724.3824.4824.7623.94152,367
2017-02-0330.5330.88531.0429.87548,307
2017-02-0229.7330.3030.7029.555151,670
2017-02-0130.0529.9130.09528.79284,467

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1435,86943,89981.7080Short
2018-12-13108,942140,83677.3538Short
2018-12-129,983349,1392.8593Cover
2018-12-1115,00122,24467.4384Short
2018-12-1014,53122,41264.8358Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TBPH.


About Theravance Biopharma, Inc. (NASDAQ: TBPH)

Logo for Theravance Biopharma, Inc. (NASDAQ: TBPH)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: TBPH)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 01 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 19 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: March, 21 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 06 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: February, 28 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 15 2018

       

       


      Daily Technical Chart for (NASDAQ: TBPH)

      Daily Technical Chart for (NASDAQ: TBPH)


      Stay tuned for daily updates and more on (NASDAQ: TBPH)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: TBPH)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TBPH is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of TBPH and does not buy, sell, or trade any shares of TBPH. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/